Anti-biofilm screening assays

Abstract

Procedures are provided to evaluate the effectiveness of slow-acting antibacterial agents such as metal salts on reduction of bacterial oral biofilm. In the modified process, the exposure time of the agent is increased from the usual 3 minutes to 7-15 minutes, e.g., about 10 minutes, and the duration increased to 5-12 days, e.g., about 8 days instead of the conventional 3 days.

Claims

1. A method of measuring the efficacy of a test composition against oral bacterial biofilm formation, comprising a) Coating a sample with saliva and placing the sample in a flow of a buffered medium, with temperature, flow and pH adjusted to approximate conditions in the mouth; wherein the sample is selected from a tooth section and hydroxyapatite disc; b) Exposing the sample to a test composition, then reinstating the flow of buffered medium, wherein the period of exposure to a test compound is from 7-15 minutes; c) Repeating the preceding step from one to four times per day for 5-12 days; d) Vortexing the sample in anaerobic media to obtain a suspension and measuring the optical density thereof, wherein the optical density is a measure of the degree of bacterial growth; e) Culturing the suspension on a solid media and counting the number of colony forming units after a period of 2-5 days, wherein the number of colony forming units is a measure of the degree of bacterial growth, and wherein the culturing is carried out in the presence of a metal salt which reacts with volatile sulfur compounds formed in steps a-c to form a black precipitate; and wherein said test composition further comprises zinc oxide and zinc citrate.

2. The method of claim 1 wherein the period of exposure the sample to a test composition in step b) is for a period of about 10 minutes.

3. The method of claim 1 wherein the step of repeating step b) is carried out from one to four times per day for about 8 days.

4. The method of claim 1 wherein the buffered medium comprises nutrients as required to support bacterial growth.

5. The method of claim 1 wherein the solid media is an agar plate and the metal salt is lead acetate.

6. The method of claim 1 wherein any black colony forming units are counted independently from the other colony forming units and wherein the number of black colony forming units corresponds to the degree of growth of bacteria which produce volatile sulfur compounds.

7. The method of claim 1 wherein the test composition is an oral care product.

Description

DESCRIPTION OF THE INVENTION

(1) The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.

(2) The invention provides, in one embodiment, a method (Method 1) of measuring the efficacy of a test composition (for example a toothpaste or mouthwash) against oral bacterial biofilm growth, comprising a) Coating a dental sample, selected from a tooth section and a hydroxyapatite disc, with saliva and placing the sample in a flow of a buffered medium, wherein temperature, flow and pH adjusted to approximate conditions in the mouth and wherein the buffered medium comprises nutrients similar to those in the mouth; b) Exposing the dental sample to a test composition, then reinstating the flow of buffered medium, wherein the period of exposure to a test compound is from 7-15 minutes, e.g. 8-12 minutes, e.g., about 10 minutes; c) Repeating the preceding step from one to four times per day for 5-12 days, e.g., for 6-10 days, e.g., for about 8 days; d) Vortexing the dental sample in anaerobic media to obtain a suspension and measuring the optical density thereof, wherein a lower optical density indicates that the test composition is more effective against oral biofilm growth.
For example, the invention provides 1.1. Method 1 wherein the period of exposure the dental sample to a test composition in step b) is for a period of about 10 minutes. 1.2. Method 1 or 1.1 wherein the step of repeating step b) is carried out from one to four times per day for about 8 days: 1.3. Any preceding method wherein the buffered medium comprises nutrients as required to support bacterial growth, e.g., comprising phosphate buffer, sugar, amino acids, and essential vitamins and minerals. 1.4. Any preceding method further comprising the step of culturing the suspension on a solid media and counting the number of colony forming units after a period of 2-5 days, wherein a lower number of colony forming units indicates that the test composition is more effective against oral biofilm growth. 1.5. Method 1.4 wherein the culture on solid media is carried out in the presence of a metal salt, e.g., an iron or lead salt, which reacts with a volatile sulfur compound formed in step a-c, e.g., hydrogen sulfide, to form a black precipitate, e.g., a metal sulfide. 1.6. Method 1.5 wherein the solid media is an agar plate and the metal salt is lead acetate. 1.7. Method 1.4 or 1.5 wherein any black colony forming units are counted independently from the other colony forming units and wherein a lower number of black colony forming units indicates that the test composition is more effective against oral biofilm growth comprising bacteria that produce volatile sulfur compounds. 1.8. Any preceding method wherein the test composition is an oral care product. 1.9. Any preceding method wherein the test composition comprises at least 0.1% of a metal ion having a valence of +2 or +3, e.g. Zn.sup.2+ or Sn(II).sup.2+. 1.10. Method 1.9 comprising measuring the uptake of the metal ion from the test composition by the dental sample, wherein greater uptake of the metal ion by the dental sample corresponds to the greater efficacy of the oral care product against oral biofilm formation.

(3) Buffered medium as used in step a) above may be any suitable medium as known in the art for allowing biofilm growth. See, for example, the various media described in Lemos, et al., Methods Mol Biol. 2010; 666: 87-102, the contents of which are incorporated herein by reference. A typical medium thus comprises phosphate buffer, sugar, amino acids, and essential vitamins and minerals, and is adjusted to approximately pH and osmolality approximating natural saliva.

(4) For example, one exemplary medium is made up of 58 mM K.sub.2HPO.sub.4, 15 mM KH.sub.2PO.sub.4, 10 mM (NH.sub.4)2SO.sub.4, 35 mM NaCl, 0.8% (wt/vol) glucose, 0.2% (wt/vol) Casamino Acids (CAA), and 100 mM MnCl.sub.2.4H.sub.2O (pH 7.4) and is supplemented with filter-sterilized vitamins (0.04 mM nicotinic acid, 0.1 mM pyridoxine HCl, 0.01 mM pantothenic acid, 1 M riboflavin, 0.3 M thiamin HCl, and 0.05 M d-biotin), amino acids (4 mM 1-glutamic acid, 1 mM L-arginine HCl, 1.3 mM 1-cysteine HCl, and 0.1 mM 1-tryptophan), and 2 mM MgSO.sub.2.7H.sub.2O.

(5) The dental samples as used herein are preferably saliva-coated hydroxyapatite discs. The saliva inoculates the discs with natural oral bioflora. Hydroxyapatite discs are commercially available, e.g., from Clarkson Chromatography Products, Inc. Hydroxyapatite, also called hydroxyapatite, is a naturally occurring mineral form of calcium apatite with the formula Ca.sub.5(PO.sub.4).sub.3(OH). The formula is usually written Ca.sub.10(PO.sub.4).sub.6(OH).sub.2 to denote that the crystal unit cell comprises two entities. Dental enamel and dentin arc comprised primarily of carbonated calcium-deficient hydroxyapatite.

(6) Use of metal salts to detect the presence Of bacteria producing volatile sulfur compounds is based on the fact that volatile sulfides such as hydrogen sulfide react with metal ions, for example Fe(II).sup.++ or Pb(II).sup.++, to form metal sulfides, which may be considered the salts of hydrogen sulfide. Metal sulfides generally have a dark color. Lead(II) acetate paper or media may be used to detect hydrogen sulfide, for example, because it turns grey or black in the presence of the gas as lead(II) sulfide is produced. Various media containing iron compounds also allow detection of hydrogen sulfide production, for example Sulfide-Indole-Motility (SIM) medium or triple sugar iron agar (TSIA), both of which contain Fe(II).sup.++, which reacts with hydrogen sulfide to produce FeS as a black precipitate.

(7) As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.

(8) Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.

EXAMPLES

(9) Embodiments of the present invention are further described in the following examples. The examples are merely illustrative and do not in any way limit the scope of the invention as described and claimed.

Example 1

Conventional Protocol Design

(10) A method of dynamic biofilm system based on conventional protocols is used to study the effect of actives on oral biofilm developed from salivary microflora. Saliva coated hydroxyapatite (HAP) discs are placed in the flow cell and connected to a one flow medium passage. The medium flows from the reservoir through the flow cells and is removed as the waste. Untreated sample/placebo is used as a control to test the efficacy of the dentrifices. Treatment solutions of 1:10 diluted dentifrices (30 ml) are then drawn into the flow cells to contact the disks for 1 minute. The flow of media is reinstated to rinse the treated discs and further allow the growth of biofilm during the study period of three days. The treatment is repeated over a time interval of 24 hours with the flow adjusted to stimulate conditions in the human mouth.

(11) The HAP discs are collected at the end of the study and introduced into anaerobic media, and vortexed to make the plaque on the disc thoroughly suspend in the solution. 300 l of the suspension is pipeted into the wells of a 96-well microplate, and the optical density (OD) at 610 nm is read using a microplate reader. Means and standard deviation of the different treatments are calculated. The lower the OD, the lower the bacteria level, and the better the efficacy of the treatment.

(12) The suspension from the flowcell is collected and diluted serially with anaerobic transfer media. Serial dilutions are plated on lead acetate plates and incubated anaerobically at 37 C. for 2-3 days. The real colony forming units on the HAP disc are counted and the final result is reported as Log cfu/disc. The lower the value, the better the efficacy of the treatment.

(13) The lead acetate reacts with sulfur to form a black deposit, so the black colonies on the plates can be counted independently as an evaluation for a product's efficacy against bacteria producing volatile sulfur compounds. This is of interest because bacteria which produce volatile Sulfur compounds are thought to be major contributors to halitosis.

(14) Prototype formulations are prepared as set forth in the table below.

(15) TABLE-US-00001 TABLE 1 Comparison of different zinc prototype formulations Con- Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 trol 1% ZnO 1% ZnO + 0.5% Zn 2% Zn 0.5% ZnO + 2% Zn 1% ZnO in 1% ZnO + 0.5% Zn (CAS) in chalk Citrate in chalk Citrate in silica Citrate in silica silica Citrate in silica Ingredients % % % % % % % Sorbitol(70%) 21 21 21 22 22 55 55 PEG 600 2 2 2 2 Trimethyl glycine 1.25 1.25 Xanthan 0.2 0.3 0.3 0.3 0.3 0.3 0.3 Purified Water 28.9 28.1 27.59 44.59 45.09 15.54 15.04 Carboxymethyl cellulose TMS 0.72 0.75 0.75 Carboxymethyl cellulose 2000S 1.2 1.2 0.8 0.8 Sodium Saccharin 0.27 0.35 0.35 0.3 0.3 0.3 0.3 Sodium monofluorophosphate 0.76 0.76 0.76 0.76 0.76 0.76 0.76 Sodium bicarbonate 0.5 1.0 1.0 NaOH 50% 0.1 MFIL-P 2.5 0.5 0.5 5 4 4 4 Silica abrasive (ZEO 114) 10 10 10 10 Precipitated calcium carbonate 18 (PCC) Refined natural calcium car- 22.5 bonate (NCC) NCC-India 35 35 Sodium lauryl sulfate 2. 2.0 2.0 2 2. 2 2 Benzyl alcohol 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Flavor 1 1.2 1.2 1.3 1.3 1.3 1.3 Tetrasodium pyrophosphate 0.5 1 1 1 1 0.5 0.5 (TSPP) Tetrapotassium pyrophosphate 1 1 2 2 (TKPP) Zinc oxide 1 1 0.5 1 1 Zinc citrate 0.5 2 2 0.5 Titanium dioxide 0.75 0.75 0.75 Pearlescent white pigment 0.25 0.25 0.25 (Timiron) Small particle silica (AC43) 5 5 5 5 5 5 Total 100 100 100 100 100 100 100

(16) The results of the study with the above-described method (3 days) are outlined in Tables 2-4 below. The formulations tested include the prototype formulations, and also commercial toothpaste products Colgate Total and Crest ProHealth, which contain triclosan and stannous fluoride respectively as antibacterial agents.

(17) TABLE-US-00002 TABLE 2 OD at 610 nm of the harvested HAP disc with three different inoculum sources (3 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 Sample Description Avg. Avg. Avg. Mean CAS control 0.43 0.59 0.33 0.45 Crest ProHealth HW 0.31 0.46 0.24 0.34 (2% Zinc citrate) 1% ZnO in chalk 0.24 0.47 0.19 0.30 360 WMH (2% Zn citrate) 0.25 0.33 0.23 0.27 1% ZnO + 0.5% Zn 0.08 0.37 0.36 0.27 citrate in chalk 1% ZnO in silica 0.15 0.47 0.12 0.25 1% ZnO + 0.5% Zinc 0.23 0.28 0.22 0.24 citrate in silica Total whitening 0.19 0.19 0.16 0.18 (triclosan)

(18) TABLE-US-00003 TABLE 3 Values of plate count on Neomycin Vancomycin agar (3 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 log log log Sample Description CFU/disc CFU/disc CFU/disc Mean CAS control 7.01 7.06 6.93 7.00 1% ZnO in chalk 6.66 6.80 6.87 6.78 1% ZnO + 6.5% Zn 6.63 6.78 6.71 6.71 citrate in chalk 360 WMH (2% Zn citrate) 6.57 6.66 6.74 6.66 Crest ProHealth HW 6.59 6.64 6.54 6.59 (2% Zinc citrate) 1% ZnO in silica 6.53 6.40 6.54 6.49 1% ZnO + 0.5% Zinc 6.09 6.36 6.50 6.32 citrate in silica Total whitening 5.26 4.92 5.94 5.38 (triclosan) CFUcolony forming units

(19) TABLE-US-00004 TABLE 4 Values of plate count on Lead Acetate agar (3 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 log log log Sample Description CFU/disc CFU/disc CFU/disc Mean CAS control 6.75 6.89 6.82 6.82 1% ZnO in chalk 6.53 6.69 6.77 6.66 1% ZnO + 0.5% Zn 6.39 6.63 6.48 6.50 citrate in chalk Crest ProHealth HW 6.36 6.52 6.16 6.38 (2% Zinc citrate) 1% ZnO in silica 6.31 6.26 6.41 6.33 360 WMH (2% Zn citrate) 5.91 6.02 6.11 6.01 1% ZnO + 0.5% Zinc 5.72 5.84 5.94 5.83 citrate in silica Total whitening 5.04 5.08 5.53 5.22 (triclosan) CFUcolony forming units

Example 2

Modified Dynamic Biofilm Protocol Design

(20) The experiment is then modified to be more representative of the actual in vivo situation. Saliva coated HAP disks are placed in the flow cell and connected to a one flow medium passage. The medium flows from the reservoir through the flow cells and is removed to waste. Untreated sample/placebo is used as a control to test the efficacy of the dentrifices. Treatment solutions of 1:10 diluted dentifrices (30 ml) are then drawn into the flow cells to contact the disks for 10 minutes. The flow of media is reinstated to rinse the treatment and further allow the growth of biofilm during the study period. The treatment is repeated over a time interval of 24 hours with the flow adjusted to stimulate conditions in the human mouth.

(21) The treatment regime is increased to 8 days. The HAP disks are collected at the end of the study and introduced into anaerobic media, and vortexed to suspend the plaque on the disc thoroughly in the solution. 300 l of the suspension is pipetted into the wells of a 96-well microplate, and optical density (OD) is read at 610 nm in the microplate reader. An Excel spreadsheet is used to calculate means and standard deviation of the different treatments. The lower the OD, the better the efficacy of the treatment.

(22) The suspension from the flowcell is collected and diluted serially with anaerobic transfer media. Serial dilutions are plated on lead acetate plates and incubated anaerobically at 37 C. for 2-3 days. The real colony forming units on the HAP disc are counted and the final result reported as Log CFU/disc. The lower the value, the better the efficacy of the treatment.

(23) The black colonies on the plates are counted independently as an evaluation for the product's anti-VSC efficacy.

(24) The following changes are made to the more conventional method of example 1 with respect to treatmentbiofilm interaction, while keeping the working principle of the method constant. In the modified method the treatment regime is increased to 8 days in place of 3 days. The contact time is also increased to 10 minutes from 1 minute. The rest of the procedure is repeated as is with harvesting after completion of 8 days. The differentiation between in the individual values of the results is found to be significant.

(25) The results are summarized in Tables 5-7 below:

(26) TABLE-US-00005 TABLE 5 OD at 610 nm of the harvested HAP disc with three different inoculum sources (8 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 Sample Description Avg. Avg. Avg. Mean CAS control 1.50 1.36 1.44 1.43 Crest ProHealth HW 1.12 1.18 1.20 1.17 (2% Zinc citrate) 1% ZnO in chalk 1.10 1.04 0.94 1.03 1% ZnO + 0.5% Zn 0.82 0.76 0.92 0.84 citrate in chalk 360 WMH (2% Zn citrate) 0.64 0.58 6.66 6.63 1% ZnO in silica 0.51 0.62 0.68 0.60 1% ZnO + 0.5% Zinc 0.35 0.48 0.42 0.42 citrate in silica Total whitening 0.25 0.31 0.34 0.30 (triclosan)

(27) TABLE-US-00006 TABLE 6 Values of plate count on Neomycin Vancomycin agar (8 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 log log log Sample Description CFU/disc CFU/disc CFU/disc Mean CAS control 7.32 7.46 7.55 7.44 Crest ProHealth HW 7.00 6.64 6.54 6.73 (2% Zinc citrate) 1% ZnO in chalk 6.28 6.24 6.49 6.34 1% ZnO + 0.5% Zn 5.95 6.12 6.20 6.09 citrate in chalk 360 WMH (2% Zn 5.85 6.02 6.35 6.08 citrate) 1% ZnO in silica 5.72 5.98 6.04 5.91 1% ZnO + 0.5% 5.67 5.75 5.59 5.67 Zinc citrate in silica Total whitening 4.95 4.86 5.02 4.94 (triclosan) CFUcolony forming units

(28) TABLE-US-00007 TABLE 7 Values of plate count on Lead Acetate agar (8 day study) - data grouped with Tukey method at 95% confidence level Subject 1 Subject 2 Subject 3 log log log Sample Description CFU/disc CFU/disc CFU/disc Mean CAS control 6.13 6.24 6.49 6.28 1% ZnO in chalk 5.82 5.74 5.95 5.84 Crest ProHealth HW 5.72 5.56 5.63 5.63 (2% Zinc citrate) 1% ZnO + 0.5% Zn 5.58 5.46 5.60 5.55 citrate in chalk 360 WMH (2% Zn 5.65 5.46 5.37 5.49 citrate) 1% ZnO in silica 5.11 5.35 5.16 5.21 1% ZnO + 0.5% Zinc 4.88 4.95 5.04 4.96 citrate in silica Total whitening 4.76 4.92 4.06 4.56 (triclosan) CFUcolony forming units

(29) The modified method of this example is not only closer to the natural situation, but it does a better job of distinguishing the relative antibacterial activities of the different formulations. While the commercial Total formulation, which contains a potent antibacterial agent (triclosan) was always the most effective, the different formulations with different metal salts proved to have good activities over time, and as seen from the Tukey analysis, these differences allow separation and ranking of the different formulations, which was not possible using conventional testing, which had these formulations as statistically indistinguishable.

Example 3

Comparative Evaluation Between Data for 3 Days (Conventional) and 8 Days (Modified) Study

(30) The mean data for each prototype was compared using each of the two methods. The modified method is able to effectively differentiate statistically between the positive control (Total whitening (triclosan)) and the negative control (CAS control), and moreover is able to distinguish between different prototypes using different Zn compound combinations. This allows better selection and optimization of lead formulation based on efficacy.

(31) TABLE-US-00008 TABLE 8 Mean values of OD at 610 nm for conventional and modified method Sample Description 3 day study 8 day study CAS control 0.45 1.43 Crest ProHeatth HW (2% Zinc citrate) 0.34 1.17 1% ZnO in chalk 0.30 1.03 1% ZnO + 0.5% Zn citrate in chalk 0.27 0.84 360 WMH (2% Zn citrate) 0.27 0.63 1% ZnO in silica 0.25 0.60 1% ZnO + 0.5% Zinc citrate in silica 0.24 0.42 Total whitening (triclosan) 0.18 0.30

(32) TABLE-US-00009 TABLE 9 Mean values of plate count on NV agar with conventional and modified method Sample Description 3 day study 8 day study CAS control 7.00 7.44 Crest ProHealth HW (2% Zinc citrate) 6.59 6.73 1% ZnO in chalk 6.78 6.34 1% ZnO + 0.5% Zn citrate in chalk 6.71 6.09 360 WMH (2% Zn citrate) 6.66 6.08 1% ZnO in silica 6.49 5.91 1% ZnO + 0.5% Zinc citrate in silica 6.32 5.67 Total whitening (triclosan) 5.38 4.94 CFUcolony forming units

(33) TABLE-US-00010 TABLE 10 Mean values of plate count on Lead Acetate agar with conventional and modified method Sample Description 3 day study 8 day study CAS control 6.82 6.28 1% ZnO in chalk 6.66 5.84 Crest ProHealth HW (2% Zinc citrate) 6.38 5.63 1% ZnO + 0.5% Zn citrate in chalk 6.50 5.55 360 WMH (2% Zn citrate) 6.01 5.49 1% ZnO in silica 6.33 5.21 1% ZnO + 0.5% Zinc citrate in silica 5.83 4.96 Total whitening (triclosan) 5.22 4.56 CFUcolony forming units

Example 4

Correlation Between Zn Uptake and Biofilm Reduction Data for Conventional and Modified Method

(34) The average amount of Zn uptake on HAP is a direct measure of the ability of the compound to reduce biofilm in vivo. Over a short interval, zinc citrate has a higher uptake, but with a longer time interval, the uptake of zinc oxide increases. Thus, the available zinc is enhanced with multiple treatments of zinc oxide, resulting in increased biofilm reduction.

(35) TABLE-US-00011 TABLE 11 Average values of Zn uptake on HAP using AAS with both methods Uptake g/HAP Sample Description 3 day study 8 day study Crest ProHealth HW (2% Zinc citrate) 52 17 360 WMH (2% Zn citrate) 47 56 1% ZnO in chalk 77 99 1% ZnO + 0.5% Zn citrate in chalk 77 116 1% ZnO in silica 85 186 1% ZnO + 0.5% Zinc citrate in silica 73 190
As can be seen from the data in Table 11, the two samples with the best degree of zinc uptake also correlated with the two best samples in the 8 day biofilm protocols (i.e. 1% ZnO in silica and 1% ZnO+0.5% Zinc citrate in silica)

(36) As those skilled in the art. will appreciate, numerous changes and modifications may be made to the embodiments described herein without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the appended claims.